The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
What is the first-line of treatment for intermediate- and high-risk patients with ET?
A
B
C
D
Essential thrombocythemia (ET) is a chronic Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) disease subtype characterized by excessive proliferation of platelets, pronounced thrombosis, a high frequency of thrombotic events, and hemorrhagic risk.1 Compared with other MPN disease subtypes (myelofibrosis [MF], and polycythemia vera), ET has a favorable overall prognosis; however, the overall survival rate remains poor compared with the general population.1 Here, we provide an overview of the epidemiology, pathophysiology, diagnosis, and management of ET.
Figure 1. Essential thrombocythemia epidemiology*
*Data from Accurso, et al.1 and Li, et al.5
This results in2:
Figure 2. Essential thrombocythemia pathophysiology*
JAK2, Janus kinase 2; RBC, red blood cell, TF, tissue factor.
*Adapted from Falchi, et al.10
Created with BioRender.com
Figure 3. Most common constitutional symptoms of essential thrombocythemia*
*Adapted from Khodier and Gadó. 2
Created with BioRender.com
Figure 4. ICC of MPN and acute leukemias major and minor criteria for the diagnosis of ET*
BCR::ABL1, breakpoint cluster region::Abelson murine leukemia viral oncogene homolog 1; BM, bone marrow; CALR, calreticulin; CML, chronic myeloid leukemia; ET, essential thrombocythemia; Hb, hemoglobin; ICC, International Consensus Classification; JAK, Janus kinase; MPL, myeloproliferative leukemia virus oncogene; PMF, primary myelofibrosis; PV, polycythemia vera.
*Adapted from Arber, et al.7
According to The International Prognostic Score for ET:
The more recent Revised International Prognostic Score for ET:
Guidance on diagnosis may vary between countries (see key guidelines section).
Figure 5. Major drug classes and their cellular targets in ET*
*Adapted from Rumi and Cazzola. 8
ET, essential thrombocythemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content